Denis DELVAL is appointed CEO of LFB SA
December 21, 2017

READ MORE >

UK launches FibCLOT®, LFB’s human fibrinogen concentrate
March 1, 2017

READ MORE >

2017 Rare Disease Day: LFB’s Commitment in the Field of Rare Diseases
February 28, 2017

READ MORE >

LFB S.A. announced today the acceptance by U.S. Food and Drug Administration of the filed Biologic License Application for Coagulation Factor VIIa Recombinant, (eptacog beta activated)
January 6, 2017

READ MORE >

The LFB Group

A leader in the field of biopharmaceuticals in Europe

The LFB Group

Cultivating life-changing therapeutic proteins

The LFB Group

In the news